In the past few years, subcutaneous low molecular weight (LMW) heparins have been established as useful drugs for the prophylaxis and treatment of venous thromboembolism (1) (2) (3) . They appear to be at least as effective as standard subcutaneous or intravenous heparin (4, 5) .
Recently, two studies compared the efficacy and safety of hospital treatment of proximal vein thrombosis with i:~. standard heparin with home treatment with low molecular weight heparin (~,7) . The two studies were similar both in design and results ( Table 1 ). The conclusions of both were consistent with the feasibility of home treatment for &horbar;50% of a selected group of patients with proximal vein thrombosis. It is maintained that this approach is safe and cost effective. Due to the importance of the problem, a few considerations from physicians with great clinical experience may be indicated. Home treatment is viewed by some physician's as dangerous and unjustified. This may be so when one takes into account the different level ofsocio-medical assistance available in different countries for home confined patients.
In fact, home treatment should imply home confinement of the patients together with alertness on the part of the general practitioners taking care of them. Furthermore, it implies adequate medicosocial assistance (visits by a nurse, social worker, etc.). All of this has a cost that must be accounted for when comparing to hospital stay costs. However, it is safe to assume that the added medical needed for the home of patient a ' deep vein thrombosis (DVT) represents only a fraction of the cost that any health system or insurance company would have had to pay had the patients been treated in a hospital setting. Therefore, the main problem concerning the use of LMW heparin is related to early discharge from a hospital rather than to home treatment. Solving this problem would be useful both in assuaging the fears of physicians and reducing costs. That this is so is indirectly dem-' onstrated by the fact that -°~5~~'~ of LMW heparintreated patients enrolled in the two studies remained a few days in the hospital before being sent home.
Our institution has contributed 78 patients to the Tasman study. ' In this case, the great majority of patients were discharged early from the hospital rather than being sent home for treatment. Only a few patients were sent home without hospital admission, after having been seen in our outpatient clinic, In other institutions participating in the study, notably the Thrombosis Center of Amsterdam University, the majority of patients were treated at home from the start. Such discrepancies are due to differences in the local organization of the outpatient clinics.
In the Tasman study, altogether 36% of the patients enrolled were never admitted to a hospital and 40% were discharged early. Thus, early discharge was actuary at least as important as home treatment from the start in reducing total costs. In the other Canadian study, 253 patients were treated in the hospital with i.v. standard heparin versus 247 patients treated mainly at home with LMW heparin; -49% of the patients were treated at home initially. Thus, in this case too, early discharge from the hospital played a major role. The main features of the two studies have been compiled in Table 1 .
The incidence of recurrent thromboembolism ' was approximately the same in both studies in the two groups of patients. Cumulatively, there were 34 instances of recurrent thrombosis in the 451 patients receiving standard heparin and 27 cases in the 449 patients receiving LMW heparin (Table 1) . Bleeding was rare in both studies; it occurred in In the Tasman study, four cases of major bleeding were reported to occur in the standard heparin group. However, two of these major bleeding episodes were reported to occur several days after heparin therapy was terminated.-on the 18th and 28th day after randomization and ~ 1 ~ and 21 days after cessation of heparin therapy. This is untenable since by then, patients were under oral anticoagulant therapy and there was thus no relationship to previous heparin administration. In fact, no thrombocytopenia or other heparin-induced. complication is reported to have occurred in these patients. Therefore, these two episodes should be eliminated from the data calculation as being &dquo;heparin-unrelated.&dquo; Mortality was also approximately the same in the two studies and in the two groups of patients (Table 2 ). There were, in fact, 33 deaths among the 451 patients receiving standard heparin and 25 in the 449 patients receiving LMWH.
The potential for bleeding is thought to be a limiting factor for home treatment (8) . It is conceivable that patients would probably be better treated in a hospital setting. The groups of patients chosen for these two studies were highly selected; many were excluded (e.g., I,491 of 2,230 patients for the Canadian study and 216 of 629 for the Tasman study). Reasons for exclusions were both medical (suspicion of pulmonary embolism (PE), associated diseases, previous DVT, etc.) and logistics (geographically inaccessibility for home follow-up). Thus, early discharge or home treatment-policy seems limited to a selected group of proximal vein thrombosis patients. Results In conclusion, it is probably advisable to use the term &dquo;early discharge&dquo; rather than &dquo;home treatment.&dquo; In fact, in most cases, the latter is a consequence of the former. This approach may be more acceptable to the general practitioner and still be cost effective. A final comment is warranted. Both trials were supported by manufacturers of LMW heparins. It would be interesting to confirm these data in a trial supported by manufacturers of standard heparin. Needless to say, that this is not intended to intimate any wrong doing on the part of those in charge of the elaboration of results of the two studies in question. It is suggested only to avoid any hidden bias.
In times of skyrocketing health costs, the approach proposed by the two groups of investigators is most welcome. However, safety and efficacy should be absolutely proven in order to avoid potential severe medico-legal litigation.
